文献速递临床试验与 GCP流行病学与生物统计

替诺福韦与安慰剂预防围产期乙型肝炎传播对比研究

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.
PubMed 文献 · N Engl J Med · 2018-01-01

这项在泰国开展的多中心双盲临床试验,将HBeAg阳性且ALT≤60 IU/L的孕妇随机分配至替诺福韦组或安慰剂组,从孕28周至产后2个月用药,婴儿接受免疫球蛋白和疫苗。结果显示替诺福韦组婴儿感染率为0%(95%CI 0-2),安慰剂组为2%(95%CI 0-6),差异无统计学意义(P=0.12)。

要点

  • 在婴儿接受免疫球蛋白和疫苗的基础上,加用替诺福韦未显著降低HBV母婴传播率。
  • 替诺福韦组和安慰剂组不良事件发生率无显著差异。
  • 停药后ALT>300 IU/L发生率替诺福韦组6%、安慰剂组3%(P=0.29)。

核心结论

  • 在婴儿接受乙肝免疫球蛋白和疫苗且母婴传播率本已较低的设置下,孕妇加用替诺福韦未显著降低HBV传播率。

研究设计与样本

  • 多中心、双盲、安慰剂对照临床试验,在泰国开展,纳入331名HBeAg阳性且ALT≤60 IU/L的孕妇。
  • 随机分配至替诺福韦组(168人)或安慰剂组(163人),从孕28周至产后2个月用药。
  • 婴儿出生时接受乙肝免疫球蛋白,并在出生时及1、2、4、6月龄接种乙肝疫苗。

主要发现

  • 主要终点分析中,替诺福韦组147名婴儿无一感染(0%,95%CI 0-2),安慰剂组147名婴儿中3名感染(2%,95%CI 0-6),P=0.12。
  • 两组不良事件发生率无显著差异。
  • 停药后母体ALT>300 IU/L发生率替诺福韦组6%,安慰剂组3%(P=0.29)。

关键数值与推荐

  • 主要终点为6月龄时婴儿HBsAg阳性并经HBV DNA水平确认。
  • 样本量计算:328名孕妇可提供90%把握度检测传播率至少9个百分点的差异(预期替诺福韦组3% vs 安慰剂组12%)。

临床怎么用

  • 对于HBeAg阳性且ALT≤60 IU/L的孕妇,在婴儿接受标准免疫预防的基础上,加用替诺福韦的额外获益未获证实。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin. METHODS: In this multicenter, double-blind clinical trial performed in Thailand, we randomly assigned hepatitis B e antigen (HBeAg)-positive pregnant women with an alanine aminotransferase level of 60 IU or less per liter to receive tenofovir disoproxil fumarate (TDF) or placebo from 28 weeks of gestation to 2 months post partum. Infants received hepatitis B immune globulin at birth and hepatitis B vaccine at birth and at 1, 2, 4, and 6 months. The primary end point was a hepatitis B surface antigen (HBsAg)-positive status in the infant, confirmed by the HBV DNA level at 6 months of age. We calculated that a sample of 328 women would provide the trial with 90% power to detect a difference of at least 9 percentage points in the transmission rate (expected rate, 3% in the TDF group vs. 12% in the placebo group). RESULTS: From January 2013 to August 2015, we enrolled 331 women; 168 women were randomly assigned to the TDF group and 163 to the placebo group. At enrollment, the median gestational age was 28.3 weeks, and the median HBV DNA level was 8.0 log10 IU per milliliter. Among 322 deliveries (97% of the participants), there were 319 singleton births, two twin pairs, and one stillborn infant. The median time from birth to administration of hepatitis B immune globulin was 1.3 hours, and the median time from birth to administration of hepatitis B vaccine was 1.2 hours. In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12). The rate of adverse events did not differ significantly between groups. The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29). CONCLUSIONS: In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials.gov number, NCT01745822 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med. 2018. PMID: 29514030. doi:10.1056/NEJMoa1708131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。